Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch

Central banks are openly debating future rate moves as inflation data sends mixed signals. That kind of uncertainty keeps many investors on the sidelines. It also creates room for fast growing stocks with high insider ownership, where managers and shareholders are clearly aligned. This article looks at three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit that profile right now.

The stocks covered below are only a starting sample from this theme, and the full screen surfaced 98 more companies with similarly aligned insiders and growth stories that are not covered here. If you want to go straight to the source and size up this wider opportunity set, analyze and filter the full list through the Fast Growing Stocks With High Insider Ownership screener.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is a West Africa focused gold company, with its growth story anchored to the Bankan Gold Project in northeast Guinea, a large exploration and development project that drives much of the optimism from analysts and management. The company also has producing gold mines in the region, but Bankan is the clearest link to the fast growing, high insider alignment theme that draws investors to this screener.

Market Cap: A$4.5b

Predictive Discovery gives you exposure to a West African gold producer that is already pouring gold from two mines while working to convert the Bankan Gold Project into its next major production hub, which is a key reason analysts forecast strong growth over the next few years. The company’s 9.5 million ounce resource base and 4.5 million ounces in reserves underpin those expectations, and recent guidance reaffirmed for 2026 gold output suggests management confidence in the production profile. At the same time, short cash runway, reliance on higher risk funding and permitting uncertainty in Guinea mean the story is far from low risk. If you are comfortable weighing that trade off, Predictive Discovery may warrant a closer look in this screener theme.

Accelerating production plans at Bankan are only half the story for Predictive Discovery. For a clearer understanding of how its growth ambitions compare with funding and permitting pressures, read the analysis report for Predictive Discovery.

Build your own high growth, high insider ownership shortlist

Predictive Discovery and the two other stocks in this article all came from the same Simply Wall St screener, and you can set up your own filters the same way. Use our customisable Screener to mix growth, valuation and risk checks for your watchlist, or lean on our curated Investing Ideas if you prefer starting from pre built themes.

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech that develops mesenchymal cell therapies such as Remestemcel L for severe inflammatory and cardiovascular diseases, with late stage programs in steroid refractory acute graft versus host disease, inflammatory bowel disease, chronic heart failure and chronic low back pain. These late stage, partnership backed candidates are the clearest link to the Fast Growing Stocks With High Insider Ownership theme because they concentrate Mesoblast’s growth potential in a handful of advanced, scalable products rather than a broad set of early experiments.

Operations: Mesoblast currently generates about US$65 million in revenue from developing its cell technology platform for commercialization.

Market Cap: A$3.3b

Mesoblast gives you exposure to a late stage regenerative medicine story where Remestemcel L and partnered MPC heart programs sit at the point where cell therapy can begin to move from promise to commercial reality. Analysts see growth potential in revenue and earnings if Phase III data and regulatory milestones go to plan, yet the stock remains tied to a development stage risk profile with funding needs and an unprofitable track record. Recent progress, including completion of patient treatment in the rexlemestrocel L chronic low back pain trial and growing Ryoncil sales, shows commercial traction. If you are prepared to weigh ambitious growth targets against clinical, financing and execution risks, Mesoblast is a company that may merit much closer attention within this screener theme.

Mesoblast’s late stage cell therapy pipeline is tied to big growth objectives, yet the real story sits in how expectations line up with upcoming milestones. Get the analyst forecasts for Mesoblast before the next update shifts the picture.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and commercialises precision radiopharmaceuticals that help doctors both find and treat cancers, with its growth story most closely tied to its prostate and kidney cancer pipeline, including TLX591 in Phase 3 and products such as Illuccix, Gozellix and TLX250/TLX250 Px. While Telix also earns revenue from broader imaging and manufacturing activities, the precision medicine pipeline is the clearest link to the Fast Growing Stocks With High Insider Ownership theme because it concentrates management and analyst expectations on a set of late stage, higher impact products rather than on small exploratory projects.

Market Cap: A$5.9b

Telix Pharmaceuticals is on many investors’ radar because its radiopharmaceuticals already support cancer imaging in more than 20 countries, while late stage therapies like TLX591, TLX250 Tx and programs such as ProstACT Global and LUTEON aim to turn that imaging reach into treatment revenue. Forecasts for earnings growth and an anticipated move into profitability over the next few years reflect that potential, and some investors see additional upside from the current discount to analyst fair value estimates. The trade off is clear: this is a company still investing heavily in R&D, reliant on higher risk funding and exposed to trial and regulatory outcomes that could either accelerate commercial traction or push key revenue streams further out.

Telix Pharmaceuticals is already generating cancer imaging revenue, yet many investors still treat it like an early stage bet. Go deeper into the late stage pipeline and commercial picture with the analysis report for Telix Pharmaceuticals

Seeking Fresh Alternatives Before They Fly

Markets move fast and fresh ideas can turn into crowded trades quickly. Scan these curated stock lists before momentum is fully caught by the crowd and act now.

• Target dependable income from companies built to keep paying by reviewing the 6 dividend fortresses while yields still look attractive and sentiment has not fully caught up.
• Hunt for early leaders in robotics and automation by running the 38 robotics and automation stocks before capital flows chase these themes and valuation gaps start dropping away.
• Position ahead of potential AI infrastructure breakouts by checking the 54 AI infrastructure stocks while many of these enablers remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com